Cerus (NASDAQ:CERS) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $31.48 million which beat the analyst consensus estimate of $31.48 million by 0.01 percent. This is a 46.42 percent increase over sales of $21.50 million the same period last year.
Valneva Shares Plunge As UK Terminates COVID-19 Vaccine Contract: What You Need Know
The U.K. government has terminated its COVID-19 vaccine contract with Valneva SE (NASDAQ:VALN) over alleged breach of obligations. Related Content: Valneva Initiates Rolling…
